Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Depression, Depression, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 1/12/2019 |
| Start Date: | November 2, 2017 |
| End Date: | June 2019 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind,
parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I
or Bipolar II disorder having a major depressive episode.
parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I
or Bipolar II disorder having a major depressive episode.
Major Inclusion Criteria:
- male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis
of Bipolar I or Bipolar II disorder
- experiencing a current major depressive episode
- able to provide written informed consent
Major Exclusion Criteria:
- any female subject who is pregnant or breast-feeding
- any subject judged to be medically inappropriate for study participation
We found this trial at
11
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials